Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2024
Price :
$35
*
At a glance
- Drugs CT 1812 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Acronyms SHINE
- Sponsors Cognition Therapeutics
- 01 Apr 2024 According to a Cognition Therapeutics media release, today announced it will host a virtual KOL event on Friday, April 12, 2024 from 8:00 AM to 9:30 AM ET. The KOLs and Cognition management will discuss CT1812 which includes the Phase 2 START Study in people with early stage disease.
- 26 Mar 2024 According to a Cognition Therapeutics media release, enrollment completed of 153 adults.
- 06 Mar 2024 According to a Cognition Therapeutics media release, company looking forward to analyzing samples from SHINE study in 153 people with Alzheimer's disease so that we a more robust set of biomarkers of CT1812 treatment can be build.